AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: AZ505 is a highly potent, substrate-competitive inhibitor of SET and MYND domain-containing protein 2 (SMYD2), with an IC₅₀ of 0.12 μM and a K_i of 0.3 μM, exhibiting minimal off-target activity against related methyltransferases (IC₅₀ > 83.3 μM for SMYD3, DOT1L, and EZH2) (Chen et al. 2023). AZ505 inhibits histone and non-histone substrate methylation, affecting key pathways in cancer and fibrosis models [APExBIO Product Page]. Its selectivity and solubility parameters make it suitable for robust in vitro studies of epigenetic regulation. Peer-reviewed evidence shows that AZ505 can reduce fibrosis and inflammatory cytokines in cisplatin-induced chronic kidney disease (CKD) models (Chen et al. 2023). AZ505 is for research use only and should be handled per solubility and storage guidelines.

Biological Rationale

SMYD2 is a protein lysine methyltransferase that methylates histone proteins (H2B, H3, H4) and non-histone targets such as p53 and Rb (Chen et al. 2023). Histone methylation is a key reversible modification influencing chromatin structure and transcriptional regulation. Aberrant SMYD2 activity is implicated in tumorigenesis, particularly through methylation of tumor suppressors and histone marks like H3K36. Overexpression of SMYD2 has been documented in various cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC). In renal disease models, increased SMYD2 expression has been linked to the progression of fibrosis and inflammation. Targeted inhibition of SMYD2 provides a precise method for dissecting these disease mechanisms and evaluating therapeutic interventions.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 acts as a substrate-competitive inhibitor by binding to the peptide substrate binding groove of SMYD2. This blocks access of both histone and non-histone protein substrates to the active site, preventing their methylation. Unlike S-adenosylmethionine (SAM)-competitive inhibitors, AZ505 does not compete with the methyl donor SAM, but specifically excludes peptide substrates. This confers high selectivity and decreases the likelihood of off-target effects. In biochemical assays, AZ505 inhibits SMYD2 with an IC₅₀ of 0.12 μM and a K_i of 0.3 μM under standard reaction conditions (25°C, Tris-HCl buffer, 50 mM, pH 8.0). For other methyltransferases (SMYD3, DOT1L, EZH2), the IC₅₀ exceeds 83.3 μM, confirming minimal cross-reactivity [APExBIO]. This substrate-competitive mechanism has been reviewed in detail in related articles [Contrast: The linked article focuses on mechanistic nuances, while the present article integrates new evidence from renal fibrosis models].

Evidence & Benchmarks

• AZ505 inhibits SMYD2-mediated methylation of histone H3 at lysine 36 (H3K36) in vitro (IC₅₀ = 0.12 μM) under standard buffer conditions (Chen 2023, DOI).
• AZ505 shows minimal inhibition of other histone methyltransferases (SMYD3, DOT1L, EZH2) with IC₅₀ > 83.3 μM, demonstrating high selectivity (APExBIO, product page).
• In cisplatin-induced CKD mouse models, AZ505 administration reduced SMYD2 expression, improved renal function, and decreased fibrosis and inflammatory cytokine levels (IL-6, TNF-α) (Chen 2023, DOI).
• AZ505 suppressed phosphorylation of profibrotic Smad3 and STAT3, while upregulating protective Smad7 in renal epithelial cells (Chen 2023, DOI).
• AZ505 is soluble in DMSO and retains stability at -20°C; warming to 37°C and ultrasonic shaking improve solution preparation (APExBIO, product page).
• AZ505 does not affect other methyltransferase-mediated pathways in assays at concentrations up to 80 μM (APExBIO, product page).

For more on comparative inhibitor benchmarks and translational workflows, see this article, which summarizes deployment guidance and workflow optimization. The present article incorporates updated evidence for renal and inflammatory disease models.

Applications, Limits & Misconceptions

AZ505 enables precise inhibition of SMYD2 for studies in:

• Epigenetic regulation research—mapping histone methylation effects.
• Cancer biology research—dissecting SMYD2's role in gastric cancer and ESCC.
• Fibrosis and inflammation models—including renal fibrosis in CKD.
• Mechanistic studies of non-histone methylation (e.g., p53, Rb).

AZ505 should not be used in diagnostic or clinical settings. It is optimized for in vitro and preclinical research. For a broader context on disease modeling and translational insights, this analysis discusses future applications; the current article updates with the latest renal fibrosis and selectivity evidence.

Common Pitfalls or Misconceptions

• AZ505 does not inhibit methyltransferases other than SMYD2 at relevant experimental concentrations.
• AZ505 is not a pan-epigenetic modulator; its specificity is limited to SMYD2 substrate sites.
• AZ505 is for research use only and should not be considered for clinical or diagnostic applications.
• Inadequate solubilization (failure to warm and ultrasonicate in DMSO) can result in inconsistent dosing.
• AZ505 does not reverse established fibrosis but can prevent or reduce fibrotic progression if used early in disease models.

Workflow Integration & Parameters

For optimal results, AZ505 should be dissolved in DMSO. The stock solution should be prepared by warming to 37°C and using ultrasonic shaking. Solutions should be aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles. Typical in vitro assay concentrations range from 0.1 μM to 10 μM, depending on target engagement and cell system. AZ505 is compatible with standard enzymatic, cellular, and biochemical assays for methyltransferase activity. APExBIO provides the B1255 kit for standardized research workflows. For stepwise protocols and troubleshooting, see this workflow guide—the current article clarifies solution stability and selectivity parameters.

Conclusion & Outlook

AZ505, a potent and selective SMYD2 inhibitor, is validated for high-specificity protein lysine methyltransferase inhibition in epigenetic and cancer biology research. Peer-reviewed evidence supports its application in disease models of cancer and fibrosis, with a distinct substrate-competitive mechanism and robust selectivity profile. As a research reagent from APExBIO, AZ505 provides a reliable tool for dissecting the histone methylation pathway, enabling advances in translational discovery. Ongoing studies will further define its role in therapeutic target validation and disease modeling.